Mumbai, Nov. 20 -- Natco Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Finished Dosage Formulations (FDF) manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th - August 21st, 2026. On conclusion of the inspection, the Company had received 4 (Four) observations in the Form-483.

Subsequently, the Company has received Establishment Inspection Report (EIR) from the U.S. FDA on the classification of the above referred inspection as Voluntary Action Indicated (VAI).

Published by HT Digital Content Services with permission from Capital Market....